Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lingbao Huxin Dan is a traditional Chinese medicine prescription used primarily for the treatment of various cardiovascular diseases, including paroxysmal atrial fibrillation and bradycardia arrhythmia with coronary heart disease. It is a multi-component herbal formulation whose chemical composition includes bufadienolides, diterpenoids, bile acids, phenolic acids, and triterpenoid saponins. Advanced analytical studies have identified 53 volatile compounds and 191 non-volatile components in the formula. In vivo metabolism studies have revealed both phase I (hydrolysis, oxidation, hydroxylation) and phase II (glucuronidation, methylation) metabolic reactions. Mechanistic research using network pharmacology and molecular docking suggests that its therapeutic effects may involve modulation of β1-adrenergic receptor activity and L-type calcium channel function[2][3][5][6]. The product is widely recognized in China for its effectiveness in managing cardiovascular ailments but lacks standardized quality evaluation guidelines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lingbao Huxin Dan.